Effect of increasing esomeprazole and pantoprazole doses on acid control in patients with symptoms of gastro-oesophageal reflux disease: A randomized, dose-response study

Clinical Drug Investigation

Volumn 28, Issue 6, 2008, Pages 333-343

  Wilder Smith, Clive ^a   Backlund, Anna ^b   Eckerwall, Göran ^b   Lind, Tore ^b   Fjellman, Mia ^b   Röhss, Kerstin ^b  

^a Brain Gut Research Group   (Switzerland)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

Esomeprazole, pharmacodynamics; Gastro oesophageal reflux; Pantoprazole, pharmacodynamics; Proton pump inhibitors, pharmacodynamics

Indexed keywords

ESOMEPRAZOLE; PANTOPRAZOLE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE TIME EFFECT RELATION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; FEMALE; GASTROESOPHAGEAL REFLUX; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH ACID SECRETION; STOMACH PH; UNSPECIFIED SIDE EFFECT;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; ANTI-ULCER AGENTS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GASTRIC ACIDITY DETERMINATION; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE;

EID: 43649092278     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200828060-00001     Document Type: Article

References (35)

1. Joelsson B, Johnsson F. Heartburn: the acid test. Gut 1989; 30: 1523-5
2. Bell NJ, Hunt RH. Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease. Gut 1992; 33: 118-24
3. Bell NJ, Burget D, Howden CW, et al. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992; 51 Suppl. 1: 59-67
4. Huang JQ, Hunt RH. pH, healing rate, and symptom relief in patients with GERD. Yale J Biol Med 1999; 72: 181-94
5. Hunt RH. Importance of pH control in the management of GERD. Arch Intern Med 1999; 159: 649-57
6. Miner Jr P, Katz PO, Chen Y, et al. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003; 98: 2616-20
7. Röhss K, Lind T, Wilder-Smith C. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20mg in patients with gastro-oesophageal reflux disease symptoms. Eur J Clin Pharmacol 2004; 60: 531-9
8. Kahrilas PJ, Falk GW, Johnson DA, et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. Aliment Pharmacol Ther 2000; 14: 1249-58
9. Johnson DA, Benjamin SB, Vakil NB, et al. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety. Am J Gastroenterol 2001; 96: 27-34
10. Richter JE, Kahrilas PJ, Johanson J, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001; 96: 656-65
11. Labenz J, Armstrong D, Lauritsen K, et al. A randomized comparative study of esomeprazole 40mg versus pantoprazole 40mg for healing erosive esophagitis: the EXPO study. Aliment Pharmacol Ther 2005; 21: 739-46
12. Labenz J, Armstrong D, Lauritsen K, et al. Esomeprazole 20mg vs. pantoprazole 20mg for maintenance therapy of healed erosive esophagitis: results from the EXPO study. Aliment Pharmacol Ther 2005; 22: 803-11
13. Jones R, Liker HR, Ducrotté P. Relationship between symptoms, subjective well-being and medication use in gastro-oesophageal reflux disease. Int J Clin Pract 2007; 61: 1301-7
14. Vaezi MF. 'Refractory GERD': acid, nonacid, or not GERD? Am J Gastroenterol 2004; 99: 989-90
15. Fass R, Shapiro M, Dekel R, et al. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease: where next? Aliment Pharmacol Ther 2005; 22: 79-94
16. Wilder-Smith C, Lind T, Lundin C, et al. Acid control with esomeprazole and lansoprazole: a comparative dose-response study. Scand J Gastroenterol 2007; 42: 157-64
17. Wilder-Smith CH, Gennoni MA, Triller J, et al. Is a fluoroscopic verification of the electrode position necessary in ambulatory intragastric pH monitoring? Digestion 1992; 52: 1-5
18. Röhss K, Wilder-Smith C, Nauclér E, et al. Esomeprazole 20mg provides more effective intragastric acid control than maintenance-dose rabeprazole, lansoprazole or pantoprazole in healthy volunteers. Clin Drug Invest 2004; 24: 1-7
19. Miner Jr PB, Tutuian R, Castell DO, et al. Intragastric acidity after switching from 5-day treatment with intravenous pantoprazole 40 mg/d to 5-day treatment with oral esomeprazole 40 mg/d or pantoprazole 40 mg/d: an open-label crossover study in healthy adult volunteers. Clin Ther 2006; 28: 725-33
20. Miehlke S, Madisch A, Kirsch C, et al. Intragastric acidity during treatment with esomeprazole 40mg twice daily or pantoprazole 40mg twice daily: a randomized, two-way crossover study. Aliment Pharmacol Ther 2005; 21: 963-7
21. Hatlebakk JG, Katz PO, Kuo B, et al. Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40mg daily. Aliment Pharmacol Ther 1998; 12: 1235-40
22. Johnson, LF, DeMeester TR. Development of the 24-hour intraesophageal pH monitoring composite scoring system. J Clin Gastroenterol 1986; 8: 52-8
23. Katz PO, Ginsberg GG, Hoyle PE, et al. Relationship between intragastric acid control and healing status in the treatment of moderate to severe erosive esophagitis. Aliment Pharmacol Ther 2007; 25: 617-28
24. Chiba N, de Gara CJ, Wilkinson JM, et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112: 1798-810
25. Edwards SJ, Lind T, Lundell L. Systematic review: proton pump inhibitors (PPIs) for the healing of reflux esophagitis. A comparison of esomeprazole with other PPIs. Aliment Pharmacol Ther 2006; 24: 743-50
26. Scholten T, Gatz G, Hole U. Once-daily pantoprazole 40mg and esomeprazole 40mg have equivalent overall efficacy in relieving GERD-related symptoms. Aliment Pharmacol Ther 2003; 18: 587-94
27. Gillessen A, Beil W, Modlin IM, et al. 40mg pantoprazole and 40mg esomeprazole are equivalent in the healing of esophageal lesions and relief from gastroesophageal reflux disease-related symptoms. J Clin Gastroenterol 2004; 38: 332-40
28. Glatzel D, Abdel-Qader M, Gatz G, et al. Pantoprazole 40mg is as effective as esomeprazole 40mg to relieve symptoms of gastroesophageal reflux disease after 4 weeks of treatment and superior regarding the prevention of symptomatic relapse. Digestion 2007; 74: 145-54
29. Vcev A, Begic I, Ostojic R, et al. Esomeprazole versus pantoprazole for healing erosive oesophagitis. Coll Antropol 2006; 30: 519-22
30. Gillessen A. Response to Madisch, Kuhlisch and Meihlke. J Clin Gastroenterol 2005; 39: 172-3
31. Madisch A, Kuhlisch E, Miehlke S. A randomized controlled trial of equivalence between pantoprazole and esomeprazole that does not have the power to conclude [letter]. J Clin Gastroenterol 2005; 39: 172
32. Goh KL, Benamouzig R, Sander P, et al. Efficacy of pantoprazole 20mg daily compared with esomeprazole 20mg daily in the maintenance of healed gastroesophageal reflux disease: a randomized, double-blind comparative trial. The EMANCIPATE study. Eur J Gastroenterol Hepatol 2007; 19: 205-11
33. Galmiche J-P. EMANCIPATE study: drawing conclusions may be difficult in the absence of fundamental information [letter]. Eur J Gastroenterol Hepatol 2008; 20: 151-2
34. Labenz J. EMANCIPATE versus EXPO: different results can be explained by differing study designs [letter]. Eur J Gastroenterol Hepatol 2008; 20: 152
35. Goh K-L, Benamouzig R, Sander P, et al. Response to 'EMANCIPATE study. Drawing conclusions may be difficult in the absence of fundamental information' and 'EMANCIPATE versus EXPO: different results can be explained by differing study designs'. Eur J Gastroenterol Hepatol 2008; 20: 153-5